Thymosin Alpha-1
A 28-amino acid immune peptide used clinically for hepatitis and increasingly by longevity-focused users to support immune resilience.
Last updated: May 2026
Category
Immune / Longevity
Frequency
Twice weekly
Research
Clinical (Approved in Asia/Europe)What is Thymosin Alpha-1?
You know the feeling. Every cold that goes around the office finds you. Every flight leaves you with a sore throat. You have read about immune peptides online and now you want to know what Thymosin Alpha-1 actually does and whether it makes sense for someone living in Vietnam.
Thymosin Alpha-1, often abbreviated TA-1, is a 28-amino acid peptide fragment of prothymosin alpha. It is naturally produced by your thymus gland, the small organ behind your breastbone that trains your T-cells. As you age, your thymus shrinks, and TA-1 production declines with it. The synthetic version is called thymalfasin, sold under the brand name Zadaxin in some Asian and European countries.
TA-1 was first sequenced in 1977 by Allan Goldstein at George Washington University. It has been used clinically for hepatitis B and C treatment in parts of Asia and Europe for decades. The mechanism is not immune suppression, it is immune regulation. TA-1 helps your immune system function more effectively without overstimulating it. Browse our full peptide library for related compounds.
In Vietnam, TA-1 access is mainly through research-grade suppliers or international hospitals with hepatology departments. Zadaxin is not commonly stocked at standard pharmacies. Most expats sourcing TA-1 go through research-grade peptide suppliers or order from regional sources. For information on how this works, see the peptide legality guide.
How It Works
Toll-Like Receptor Activation: TA-1 acts on TLR-2 and TLR-9 on dendritic cells and myeloid cells. This primes your innate immune system to recognize and respond to pathogens more effectively.
T-Cell Maturation: TA-1 stimulates the maturation of T-cells, specifically CD4+ helper T-cells and CD8+ cytotoxic T-cells. This is the same function your thymus performs naturally when it is healthy.
Natural Killer Cell Activation: TA-1 enhances the activity of NK cells, your first line of defense against virally infected cells and early-stage cancer cells.
Cytokine Modulation: TA-1 reduces the production of pro-inflammatory cytokines like IL-1 beta and TNF-alpha while promoting balanced immune signaling. This is regulation, not suppression.
Benefits
- Enhanced immune response to chronic viral infections (hepatitis B/C, HPV, CMV)
- Support for aging immune systems (immunosenescence)
- Adjunct therapy potential for autoimmune conditions
- Post-illness recovery support
- Cancer adjunct in clinical settings (with oncologist oversight)
- Reduced frequency of respiratory infections in some users
- Improved vaccine response in immunocompromised patients
Dosing Protocol
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Standard Protocol | 1.5 mg | Twice weekly (sub-q) | 4-12 weeks |
| Acute Support | 0.45 mg | Daily (sub-q) | 2-4 weeks |
| Maintenance | 1.5 mg | Once weekly | Ongoing as needed |
| Clinical (Hepatitis) | 1.6 mg | Twice weekly | 6-12 months |
Always start at the lowest effective dose and titrate up gradually.
Side Effects
Common
- ⚠Mild injection site reaction (redness, minor swelling)
- ⚠Temporary fatigue in first few doses
- ⚠Mild headache reported by some users
Rare
- •Temporary elevation in ALT liver enzymes (monitor if concerned)
- •Flu-like symptoms during initial immune activation
Who Should NOT Use Thymosin Alpha-1
- ✕Pregnancy or breastfeeding (insufficient safety data)
- ✕Transplant recipients on immunosuppressants (do not stimulate rejection)
- ✕Active chemotherapy (consult oncologist first)
- ✕Intentional immunosuppression therapy (contradicts treatment goal)
What to Expect
Most users feel nothing dramatic. Some report mild fatigue or flu-like symptoms as immune system activates. This typically resolves within days.
Users focused on chronic infection support may notice subtle improvements. Energy levels often stabilize. Some report feeling "less susceptible" to whatever is going around.
Cumulative immune benefits become more apparent. Users with chronic viral loads may see improvements in relevant bloodwork. General resilience improves.
Most users complete a cycle and assess. Some continue maintenance dosing. Others cycle off and return seasonally or when immune challenges arise.
Notes from Ho Chi Minh City
Thymosin Alpha-1 is the peptide I run on a 4-week pulse protocol every time I come back from Tan Son Nhat after a long-haul flight, because the immune dip from cabin air plus the airborne load of HCMC humidity in May reliably puts me sideways for a week if I do nothing. The 1.5mg twice-weekly subcutaneous dose is the floor that actually works; the 250mcg dosing some forums recommend is a waste of vials. Zadaxin brand is not stocked at Long Châu or Pharmacity and is occasionally available through FV Hospital and Vinmec Central Park hepatology clinics at roughly 8 to 12 million VND per 5-vial box, and research-grade TA-1 runs 1.8 to 2.5 million VND per 10mg vial through cold-chain importers. The most reliable signal of effect is fewer sinus infections during the District 1 rainy season.
Sourcing in Vietnam
Branded Zadaxin (thymalfasin) is occasionally available through FV Hospital and Vinmec Central Park hepatology clinics in HCMC at roughly 8 to 12 million VND per 5-vial box, prescription-only. Research-grade TA-1 runs 1.8 to 2.5 million VND per 10mg vial through cold-chain importers. Not stocked at Long Châu, Pharmacity, or any retail pharmacy. See the supplier list and COA guide before purchasing.
FAQ
Q: Is Thymosin Alpha-1 legal in Vietnam?
A: TA-1 exists in a gray area similar to most research peptides in Vietnam. Zadaxin is approved in several Asian countries for hepatitis treatment, but not specifically registered with the DAV in Vietnam. Most users source research-grade TA-1 from regional suppliers. See the peptide legality guide for how this works in practice.
Q: What is the typical dose of TA-1?
A: The standard research dose is 1.5 mg subcutaneous, twice per week. Clinical hepatitis protocols use 1.6 mg twice weekly. Some acute protocols use 0.45 mg daily for 2-4 weeks. Underdosing at 200-500 mcg is a common mistake and unlikely to produce meaningful immune effects.
Q: How is TA-1 different from TB-500?
A: They are completely different peptides despite both containing "thymo" in the name. TB-500 (Thymosin Beta-4) is a healing peptide for tissue repair. TA-1 (Thymosin Alpha-1) is an immune modulating peptide. Different mechanisms, different uses. See TB-500 for the healing peptide.
Q: Does TA-1 cause immune suppression?
A: No. TA-1 is an immune modulator, not an immune suppressant. It enhances and regulates immune function rather than suppressing it. This is why it is contraindicated for transplant patients on immunosuppressants, because it would work against their medication.
Q: How long does a TA-1 cycle last?
A: Most research protocols run 4 to 12 weeks depending on the goal. Clinical hepatitis treatment runs 6 to 12 months. Continuous use without breaks is generally not recommended for wellness users. Many people cycle seasonally or during periods of increased immune challenge.
Q: Can I stack TA-1 with other peptides?
A: Yes. TA-1 stacks well with longevity protocols. It pairs naturally with NAD+ therapy for cellular health. It does not interact with healing peptides like BPC-157, so they can be used concurrently if needed.
Q: Where can I buy TA-1 in Vietnam?
A: Most expats source research-grade TA-1 from regional peptide suppliers with cold-chain shipping to Vietnam. Zadaxin is not commonly available at local pharmacies. Check the supply index for verified sources. Always verify batch purity with a third-party COA.
Where to Get Thymosin Alpha-1 in Vietnam
See our community-verified supplier list with COA verification and cold-chain shipping to Vietnam.
Related Peptides
Research & Sources
- Thymosin alpha 1: a comprehensive review of the literature · King R, Tuthill C · World Journal of Virology (2015) PMID: 26568911
Comprehensive review of TA-1 mechanism, indications, and clinical evidence across hepatitis and immune modulation.
- Thymosin alpha 1 and its role in viral infectious diseases: the mechanism and clinical application · Liu Y, Pan Y, Hu Z, et al. · Molecules (2021) PMID: 34577071
Mechanistic review covering TLR-2/9 activation and T-cell maturation pathways relevant to viral infection control.
- Treatment of chronic hepatitis B with thymosin alpha 1 · Andreone P, Cursaro C, Gramenzi A, et al. · Journal of Viral Hepatitis (1996) PMID: 8918015
Foundational clinical trial supporting twice-weekly 1.6mg dosing for chronic hepatitis B.
- Thymosin alpha 1 reduces mortality of severe COVID-19 by restoration of lymphocytopenia · Liu Y, Pang Y, Hu Z, et al. · Cell (2020) PMID: 32945514
Observational data on TA-1 use in severe respiratory viral infection and lymphocyte recovery.
Important Disclaimer
Educational content only. Not medical advice. Peptides discussed on this page are not approved by Vietnam’s Ministry of Health (Bộ Y Tế) or the Drug Administration of Vietnam (DAV) for the indications described. Research peptides are not stocked at Long Châu, Pharmacity, or any retail pharmacy in Vietnam. Consult a licensed physician before any use.